SCHEDULE: Millennium Entities Disclose vTv Therapeutics Stake

Several entities affiliated with Millennium Management have reported beneficial ownership of vTv Therapeutics Inc. Class A Common Stock, collectively holding approximately 6.9% of the outstanding shares.

Summary

• Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have jointly filed a Schedule 13G, indicating their beneficial ownership of vTv Therapeutics Inc. Class A Common Stock.
• The filing, dated June 30, 2026, shows that these entities collectively hold a significant stake in the company.
• Specifically, Integrated Core Strategies (US) LLC reports shared voting and dispositive power over 249,027 shares, representing 6.3% of the class.
• Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander each report shared voting and dispositive power over 269,874 shares, representing 6.9% of the class.
• The filing clarifies that the securities are held by entities subject to the voting control and investment discretion of Millennium Management LLC and/or other investment managers controlled by Millennium Group Management LLC and Mr. Englander.
• No single entity reports sole voting or dispositive power over any shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of beneficial ownership and does not provide new operational or financial information about the company.

Positives

• Significant collective ownership stake reported by established investment entities, potentially indicating confidence in the company's prospects.
• Clear disclosure of beneficial ownership through a joint filing agreement, promoting transparency.

Negatives

• The filing does not provide specific financial performance data or forward-looking guidance for vTv Therapeutics Inc., making it difficult to assess the company's operational health.
• The nature of the beneficial ownership is complex, with shares held by various entities under shared control, which may obscure direct accountability.

Risks

• The filing does not explicitly mention any risks associated with vTv Therapeutics Inc. or the reporting persons' investment strategy.
• Potential for future changes in ownership or voting power among the reporting entities could impact the stability of their collective stake.

Future Outlook

The filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding vTv Therapeutics Inc.'s future performance.

Management Comments

• The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC).
• The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.

Industry Context

StockSavvy.ai notes that significant stakes being taken by large investment management firms like Millennium can signal potential strategic interest or a belief in undervalued assets within the biotechnology sector, though this filing is purely a disclosure of holdings.

Stakeholder Impact

• Shareholders may view the increased stake by significant investment firms as a positive sign, potentially leading to increased market interest.
• The disclosure provides transparency to the market regarding the ownership structure of a portion of the company's shares.

Next Steps

• The reporting persons will continue to monitor their investment in vTv Therapeutics Inc.

Key Dates

Keywords

vTv Therapeutics, Schedule 13G, Millennium Management, Integrated Core Strategies, Beneficial Ownership, Class A Common Stock, Investment Management, SEC Filing